The expression of CXCR4 and its relationship with matrix metalloproteinase-9/vascular endothelial growth factor in esophageal squamous cell cancer

Diseases of the Esophagus

Volumn 24, Issue 4, 2011, Pages 283-290

  Lu, C L ^a   Ji, Y ^a   Ge, D ^a   Guo, J ^a   Ding, J Y ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CXCR4; Esophageal squamous cell cancer; MMP 9; Prognosis; VEGF

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GELATINASE B; PARAFFIN; VASCULOTROPIN;

ADULT; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PROGNOSIS; RECEPTORS, CXCR4; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79956204168     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2010.01135.x     Document Type: Article

References (23)

1. Tew W P, Kelsen D P, Ilson D H. Targeted therapies for esophageal cancer. Oncologist 2005; 10: 590-601.
2. Parkin D M. International variation. Oncogene 2004; 23: 6329-40.
3. Blot W J, McLaughlin J K. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26 (Suppl 15): 2-8.
4. Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003; 349 2241-52.
5. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007; 292: C987-95.
6. Burger J A, Kipps T J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-7.
7. Gockel I, Schimanski C C, Heinrich C etal. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer 2006; 6: 290.
8. Kaifi J T, Yekebas E F, Schurr P etal. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 2005; 97: 1840-7.
9. Bollschweiler E, Baldus S E, Schroder W, Schneider P M, Holscher A H. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol 2006; 94: 355-63.
10. Greenstein A J, Litle V R, Swanson S J, Divino C M, Packer S, Wisnivesky J P. Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg 2008; 206: 239-46.
11. Kris M G, Natale R B, Herbst R S etal. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
12. Sanchez-Munoz A, Perez-Ruiz E, Jimenez B etal. Targeted therapy of metastatic breast cancer. Clin Transl Oncol 2009; 11: 643-50.
13. Vihinen P, Kahari V M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-66.
14. Kleespies A, Guba M, Jauch K W, Bruns C J. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87: 95-104.
15. Hao L, Zhang C, Qiu Y etal. Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Lett 2007; 253: 34-42.
16. Liang Z, Brooks J, Willard M etal. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 2007; 359: 716-22.
17. Li J K, Yu L, Shen Y, Zhou L S, Wang Y C, Zhang J H. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World J Gastroenterol 2008; 14: 2308-13.
18. Yuecheng Y, Xiaoyan X. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur J Cancer Prev 2007; 16: 430-5.
19. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79: 206-13.
20. Chen L, Ren G S, Li F, Sun S Q. Expression of Livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma. World J Gastroenterol 2008; 14: 5749-54.
21. Mroczko B, Kozlowski M, Groblewska M etal. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer. Folia Histochem Cytobiol 2008; 46: 471-8.
22. Gu Z D, Chen K N, Li M, Gu J, Li J Y. Clinical significance of matrix metalloproteinase-9 expression in esophageal squamous cell carcinoma. World J Gastroenterol 2005; 11: 871-4.
23. Gockel I, Schimanski C C, Moehler M, Junginger T. Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4. Future Oncol 2007; 3: 119-22.